Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.

Study Overview

• Status: Completed
• Conditions: Moderate and Severe Active Rheumatoid Arthritis; Active Psoriatic Arthritis; Active Ankylosing Spondylitis; Moderately to Severely Active Crohn's Disease
• Intervention / Treatment: Drug: e-Device

• Study Type: Interventional
• Enrollment (Actual): 70
• Phase: Phase 3

Expanded Access

Available outside the clinical trial. See expanded access record.

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Mesa, Arizona, United States, 85202
      • Ra0098 116
    • Mesa, Arizona, United States, 85306
      • Ra0098 107
    • Phoenix, Arizona, United States, 85037
      • Ra0098 135
    • Tucson, Arizona, United States, 85704
      • Ra0098 119
  • California
    • Covina, California, United States, 91722
      • Ra0098 101
  • Florida
    • Clermont, Florida, United States, 34711
      • Ra0098 131
    • Coral Springs, Florida, United States, 33071
      • Ra0098 132
  • Georgia
    • Gainesville, Georgia, United States, 30501
      • Ra0098 127
  • Iowa
    • Clive, Iowa, United States, 50265
      • Ra0098 122
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Ra0098 105
    • Saint Louis, Missouri, United States, 63128
      • Ra0098 104
  • New Jersey
    • Dover, New Jersey, United States, 07801
      • Ra0098 103
  • New York
    • Great Neck, New York, United States, 11021
      • Ra0098 117
  • South Carolina
    • Myrtle Beach, South Carolina, United States, 29572
      • Ra0098 113
  • Tennessee
    • Hixson, Tennessee, United States, 37343
      • Ra0098 126
  • Texas
    • Austin, Texas, United States, 78731
      • Ra0098 111
    • Austin, Texas, United States, 78745
      • Ra0098 123
    • Austin, Texas, United States, 78758
      • Ra0098 102
    • Corpus Christi, Texas, United States, 78404
      • Ra0098 128
    • Nassau Bay, Texas, United States, 77058
      • Ra0098 106
    • San Antonio, Texas, United States, 78229
      • Ra0098 114
  • Washington
    • Richland, Washington, United States, 99352
      • Ra0098 133

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is male or female and must be at least 18 years old at Visit 1
• Subject must have been diagnosed at least 6 months prior to Visit 1 with documented moderate to severe active Rheumatoid Arthritis (RA), active Psoriatic Arthritis (PsA), active Ankylosing Spondylitis (AS) (in US), or moderately to severely active Crohn's Disease (CD) (in US)
• A minimum of 10 subjects will have impaired hand function. Impaired hand function will be measured using the Cochin scale (Duruöz et al, 1996; Poiraudeau et al, 2000) and impaired hand function will be defined as patients who have a Cochin score >= 13.5 at Baseline
• Subjects must have been prescribed Certolizumab Pegol (CZP) and must have been self-injecting CZP using the pre-filled syringe for at least 3 months prior to Visit 1. Subjects with RA, PsA, or AS must have been on a stable Q2W (every 2 weeks) or Q4W (every 4 weeks) CZP dosing regimen for at least 3 months prior to Screening. Subjects with CD must have been on a stable Q4W CZP dosing regimen for at least 3 months prior to Visit 1.
• Subjects must have been screened according to the applicable national tuberculosis (TB) screening guidelines (to be documented) or provide a documented TB screening activity (TB questionnaire, Interferon-Gamma-Release Assay (IGRA) test, or chest x-ray) within the past 12 months prior to Visit 1.
• Female subjects of childbearing potential should have a negative pregnancy test at Visit 1 and should be using a medically accepted method of contraception during the entire duration of the study. Female subjects who are postmenopausal for at least 2 years or have undergone a complete hysterectomy, bilateral tubal ligation, and/or bilateral oophorectomy, or have a congenital sterility are considered not of childbearing potential

Exclusion Criteria:

• Subject has participated in another study of an investigational medicinal product (IMP) or an investigational device within the previous 3 months or is currently participating in another study of an IMP or an investigational device
• Subject has a history of chronic alcohol or drug abuse within the previous 6 months
• Subject has a history of significant cardiovascular, respiratory, gastrointestinal, hepatic, endocrine, renal, dermatological, neurological, psychiatric, hematological, or bleeding disorders
• Subjects with known Tuberculosis (TB) infection and at high risk of acquiring TB infection. Subjects with latent TB (LTB) who have not completed the prophylactic treatment regimen for LTB 3 months prior to enrollment
• Subject has an active chronic/latent infection including but not limited to TB (untreated latent or active), hepatitis virus (HV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
• Subject has a current malignancy or a history of malignancy. Subjects with less than 3 completely excised basal cell carcinomas or with cervical carcinoma in situ successfully treated surgically more than 5 years prior to Screening may be included
• Subject has had major surgery (including joint surgery) within 8 weeks prior to Visit 1, or has a scheduled surgery during the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Certolizumab Pegol Q2W injection by e-Device; Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.	Drug: e-Device; Active Substance: Certolizumab Pegol; Pharmaceutical form: Solution for injection; Route of administration: subcutaneous injection by e-Device; Other Names: Cimzia
Experimental: Certolizumab Pegol Q4W injection by e-Device; Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.	Drug: e-Device; Active Substance: Certolizumab Pegol; Pharmaceutical form: Solution for injection; Route of administration: subcutaneous injection by e-Device; Other Names: Cimzia

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2	Safe and effective self-injection was evaluated by the healthcare provider and is defined as: Dose Delivery: Subject self-injected the complete dose of Certolizumab Pegol (CZP) as confirmed by a visual inspection of the CZP-cassette(s) which shows the pre-filled syringe container to be empty AND; No Adverse Events related to use of the e-Device (Adverse Device Effects) that would preclude continued use of the e-Device for self-injection. For subjects on the Q4W (every 4 weeks) dosing regimen who would self-inject twice (2×200 mg CZP) at each visit, each injection was evaluated for safety and effectiveness using the above criteria. The primary endpoint of safe and effective self-injection for subjects on the Q4W dosing regimen was met only if both self-injections were determined to be safe and effective.	Visit 2 (Week 2 for Q2W; Week 4 for Q4W)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 1	Safe and effective self-injection was evaluated by the healthcare provider and is defined as: Dose Delivery: Subject self-injected the complete dose of Certolizumab Pegol (CZP) as confirmed by a visual inspection of the CZP-cassette(s) which shows the pre-filled syringe container to be empty AND; No Adverse Events related to use of the e-Device (Adverse Device Effects) that would preclude continued use of the e-Device for self-injection. For subjects on the Q4W (every 4 weeks) dosing regimen who would self-inject twice (2×200 mg CZP) at each visit, each injection was evaluated for safety and effectiveness using the above criteria. The primary endpoint of safe and effective self-injection for subjects on the Q4W dosing regimen was met only if both self-injections were determined to be safe and effective.	Visit 1 (Week 0)
Percentage of Used Certolizumab Pegol (CZP)-Cassettes Identified as Having Structural Integrity Issues Based on Visual Examination	CZP-cassettes identified as having structural integrity issues meant CZP-cassettes with clear evidence of damage/compromised structural integrity, not superficial cosmetic imperfections.	During the study (from Week 0 up to Week 4)
Mean Change From Baseline in Systolic Blood Pressure	Blood pressure was measured in millimetre of mercury (mmHg).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Mean Change From Baseline in Diastolic Blood Pressure	Blood pressure was measured in millimetre of mercury (mmHg).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Mean Change From Baseline in Pulse Rate	Pulse Rate was measured in beats per minute (beats/min).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Mean Change From Baseline in Respiratory Rate	Respiratory Rate was measured in breaths per minute (breaths/min).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Mean Change From Baseline in Body Temperature	Body Temperature was measured in Grad Celsius (°C).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Incidence of Adverse Events (AEs) During the Study	An Adverse Event (AE) was any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational medicinal product (IMP), whether or not related to the medicinal (investigational) product.	During the study (from Week 0 up to Week 5 +/-3 Days)
Incidence of Adverse Device Events (ADEs) During the Study	An Adverse Device Event (ADE) was an AE related to the use of an investigational device. An ADE must have met 1 or more of the following criteria: Adverse event that resulted from insufficiencies or inadequacies in the Instructions for Use (IFU), the deployment, the implantation, the installation, the operation, or any malfunction of the investigational medical device; Adverse event that was a result of an error or intentional misuse.	During the study (from Week 0 up to Week 5 +/-3 Days)

Collaborators and Investigators

• Sponsor: UCB Biopharma S.P.R.L.

Publications and helpful links

General Publications

• Pompilus F, Ciesluk A, Strzok S, Ciaravino V, Harris K, Szegvari B, Mountian I, Cleanthous S, Meunier J. Development and psychometric evaluation of the assessment of self-injection questionnaire: an adaptation of the self-injection assessment questionnaire. Health Qual Life Outcomes. 2020 Nov 4;18(1):355. doi: 10.1186/s12955-020-01606-7.

Helpful Links

• Product Information
• FDA Safety Alerts and Recalls

Study record dates

Study Major Dates

• Study Start (Actual): November 3, 2017
• Primary Completion (Actual): July 2, 2018
• Study Completion (Actual): July 2, 2018

Study Registration Dates

• First Submitted: November 23, 2017
• First Submitted That Met QC Criteria: November 23, 2017
• First Posted (Actual): November 30, 2017

Study Record Updates

• Last Update Posted (Actual): October 25, 2019
• Last Update Submitted That Met QC Criteria: October 4, 2019
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Keywords: Certolizumab Pegol; E-Device
• Additional Relevant MeSH Terms: Digestive System Diseases; Skin Diseases; Infections; Immune System Diseases; Autoimmune Diseases; Gastrointestinal Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Gastroenteritis; Intestinal Diseases; Skin Diseases, Papulosquamous; Spinal Diseases; Bone Diseases; Inflammatory Bowel Diseases; Spondylarthropathies; Psoriasis; Bone Diseases, Infectious; Ankylosis; Arthritis; Arthritis, Rheumatoid; Crohn Disease; Arthritis, Psoriatic; Spondylitis; Spondylarthritis; Spondylitis, Ankylosing
• Other Study ID Numbers: RA0098

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No